Abstract
Psoriatic arthritis (PsA) is an inflammatory arthritis, characterized by mild arthralgia to severe joint deformities. Long term management of these diseases with nonsteroidal anti-inflammatory drugs (NSAIDs) and diseasemodifying antirheumatic drugs (DMARDs) is limited due to lack of efficacy and potential organ toxicity. Recently, the approval of injectable biologics, such as T cell inhibitors and TNF-α antagonist, has changed the treatment of moderateto- severe psoriasis and PsA. Unlike NSAIDs and DMARDs, TNF-α antagonists not only provide unambiguous benefits for the skin and joints, but also prevent the progression of structural damage in peripheral joints. Biological agents in the treatment of PsA have broad prospects. More and more biological agents are being developed for the treatment of PsA. In the current review, we will discuss the progress of biological agents on PsA.
Keywords: Biotherapy, psoriatic arthritis, T-cell modulating agents, TNF-α inhibitors.
Current Pharmaceutical Biotechnology
Title:Progress of Biological Agents on Psoriatic Arthritis
Volume: 15 Issue: 6
Author(s): Yan Li, Dashan Wang, Yantang Wang and Guixiu Shi
Affiliation:
Keywords: Biotherapy, psoriatic arthritis, T-cell modulating agents, TNF-α inhibitors.
Abstract: Psoriatic arthritis (PsA) is an inflammatory arthritis, characterized by mild arthralgia to severe joint deformities. Long term management of these diseases with nonsteroidal anti-inflammatory drugs (NSAIDs) and diseasemodifying antirheumatic drugs (DMARDs) is limited due to lack of efficacy and potential organ toxicity. Recently, the approval of injectable biologics, such as T cell inhibitors and TNF-α antagonist, has changed the treatment of moderateto- severe psoriasis and PsA. Unlike NSAIDs and DMARDs, TNF-α antagonists not only provide unambiguous benefits for the skin and joints, but also prevent the progression of structural damage in peripheral joints. Biological agents in the treatment of PsA have broad prospects. More and more biological agents are being developed for the treatment of PsA. In the current review, we will discuss the progress of biological agents on PsA.
Export Options
About this article
Cite this article as:
Li Yan, Wang Dashan, Wang Yantang and Shi Guixiu, Progress of Biological Agents on Psoriatic Arthritis, Current Pharmaceutical Biotechnology 2014; 15 (6) . https://dx.doi.org/10.2174/138920101506140910150227
DOI https://dx.doi.org/10.2174/138920101506140910150227 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Biologic Therapy in Immune Mediated Inflammatory Disease: Basic Science and Clinical Concepts
Current Drug Safety The Risk of Progressive Multifocal Leukoencephalopathy Under Biological Agents Used in the Treatment of Chronic Inflammatory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Ovarian Cancer - Angiogenesis and Targeted Therapy
Current Angiogenesis (Discontinued) Is High Oral Dose L-arginine Intake Effective in Leukoaraiosis? Preliminary Data, Study Protocol and Expert’s Opinion
Current Aging Science Safety of Systemic Biologic Agents in the Treatment of Non-malignant Skin Disorders
Current Drug Safety SAMHD1 in Retroviral Restriction and Innate Immune Sensing – Should We Leash the Hound?
Current HIV Research The Offer of Chemistry to Targeted Therapy in Cancer
Recent Patents on Biotechnology RAGE, Diabetes, and the Nervous System
Current Molecular Medicine Opiate Drug Use and the Pathophysiology of NeuroAIDS
Current HIV Research HIV-Infected Patients and Liver Transplantation: Who, When and Why
Current HIV Research Immunotherapy for Targeting Tau Pathology in Alzheimer’s Disease and Tauopathies
Current Alzheimer Research Triggering Receptor Expressed on Myeloid Cells (TREM) Family and the Application of Its Antagonists
Recent Patents on Anti-Infective Drug Discovery Human Immunodeficiency Virus-Mononuclear Phagocyte Interactions:Emerging Avenues of Biomarker Discovery, Modes of Viral Persistence and Disease Pathogenesis
Current HIV Research Microbes, Immunity and Multiple Sclerosis
Current Immunology Reviews (Discontinued) Autoimmune Neuromuscular Disorders
Current Neuropharmacology Purines and Pyrimidines: Metabolism, Function and Potential as Therapeutic Options in Neurodegenerative Diseases
Current Protein & Peptide Science STAT3 and Its Phosphorylation are Involved in HIV-1 Tat-Induced Transactivation of Glial Fibrillary Acidic Protein
Current HIV Research The Pathology Induced by Highly Active Antiretroviral Therapy Against Human Immunodeficiency Virus: an Update
Current Medicinal Chemistry Antibodies as Crypts of Antiinfective and Antitumor Peptides
Current Medicinal Chemistry Substance Abuse and Movement Disorders: Complex Interactions and Comorbidities
Current Drug Abuse Reviews